Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 13, 2018 (8 years ago)

Solco Healthcare US Valsartan and Hydrochlorothiazide

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Solco Healthcare US Valsartan and Hydrochlorothiazide, USP, 320 MG/25 MG Tablets, 90-count bottles, Rx Only, Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xynqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC Cranbury, NJ 08512 USA NDC 43547-315-09

Affected NDC 43547-0315-09

Compare with the code on your package — it is the most precise check available.

Drug: Valsartan Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Valsartan and Hydrochlorothiazide
NDC 43547-0315
VALSARTAN 320 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 Tablet, Film Coated
Oral
Solco Healthcare US, LLC Rx
Recalling firm
Prinston Pharmaceutical Inc
NDC code
43547-315-09
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0976-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Valsartan recalls

See all
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class II · Moderate risk

Valsartan Tablets 320 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-125-90 D-1055-2019
Class II · Moderate risk

Valsartan Tablets 160 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-124-90 D-1054-2019
Class II · Moderate risk

Valsartan Tablets 80 mg USP

CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products

Ongoing Nitrosamine impurity Rising Pharmaceuticals, Inc. NDC 52343-123-90 D-1053-2019

Other recalls by Prinston Pharmaceutical Inc

All 2018 recalls
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-03 D-0413-2019
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-331-09 D-0412-2019
Class II · Moderate risk

Irbesartan and Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-331-03 D-0411-2019
Class II · Moderate risk

Irbesartan and HydrochlorothiazideTablets

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Completed Nitrosamine impurity Prinston Pharmaceutical Inc NDC 43547-330-09 D-0410-2019